NDAINJECTIONINJECTABLE
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
3
Data completeness
5/8 — Partial
ANTIZOL (fomepizole) by R-Pharm US is clinical pharmacology mechanism of action: antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. Approved for ethylene glycol poisoning, methanol poisoning. First approved in 1997.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTIZOL (fomepizole) is a small-molecule competitive inhibitor of alcohol dehydrogenase used to treat acute poisoning from ethylene glycol and methanol. It works by blocking the enzyme that metabolizes these toxic compounds into lethal metabolites, thereby preventing metabolic acidosis, renal damage, and blindness. ANTIZOL is a life-saving emergency antidote administered intravenously.
LOE Approaching1.2 years to LOE
Niche emergency-use product with minimal commercial infrastructure; LOE approaching in 1.2 years signals transition planning and potential team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action: Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to…
Worked on ANTIZOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.